223 related articles for article (PubMed ID: 36580126)
1. Descriptive study of the economic burden among patients with type 2 diabetes mellitus, chronic kidney disease, and chronic kidney disease and type 2 diabetes mellitus in a large US commercially insured population.
Chung H; Crowe CL; Kong SX; Singh R; Farej R; Elliott J; Williamson T; Willey VJ
J Manag Care Spec Pharm; 2023 Jan; 29(1):80-89. PubMed ID: 36580126
[No Abstract] [Full Text] [Related]
2. Health Plan Enrollment and Disenrollment of Individuals With and Without Established Chronic Disease in a U.S. Commercially Insured and Medicare Advantage Population.
Chung H; Deshpande G; Zolotarjova J; Quimbo RA; Kern DM; Cochetti PT; Willey VJ
J Manag Care Spec Pharm; 2019 May; 25(5):612-620. PubMed ID: 31039058
[TBL] [Abstract][Full Text] [Related]
3. Annual health care resource utilization and cost among type 2 diabetes patients with newly recognized chronic kidney disease within a large U.S. administrative claims database.
Folkerts K; Petruski-Ivleva N; Kelly A; Fried L; Blankenburg M; Gay A; Kovesdy CP
J Manag Care Spec Pharm; 2020 Dec; 26(12):1506-1516. PubMed ID: 33251992
[No Abstract] [Full Text] [Related]
4. Health Care Resource Utilization and Exacerbation Rates in Patients with COPD Stratified by Disease Severity in a Commercially Insured Population.
Wallace AE; Kaila S; Bayer V; Shaikh A; Shinde MU; Willey VJ; Napier MB; Singer JR
J Manag Care Spec Pharm; 2019 Feb; 25(2):205-217. PubMed ID: 30698096
[TBL] [Abstract][Full Text] [Related]
5. Clinical and economic burdens of recurrence following nephrectomy for intermediate high- or high-risk renal cell carcinoma: A retrospective analysis of Surveillance, Epidemiology, and End Results-Medicare data.
Sundaram M; Song Y; Rogerio JW; Zhang S; Bhattacharya R; Adejoro O; Carley C; Zhu JJ; Signorovitch J; Haas NB
J Manag Care Spec Pharm; 2022 Oct; 28(10):1149-1160. PubMed ID: 36048895
[No Abstract] [Full Text] [Related]
6. Increased delay from initial concern to diagnosis of autism spectrum disorder and associated health care resource utilization and cost among children aged younger than 6 years in the United States.
Vu M; Duhig AM; Tibrewal A; Campbell CM; Gaur A; Salomon C; Gupta A; Kruse M; Taraman S
J Manag Care Spec Pharm; 2023 Apr; 29(4):378-390. PubMed ID: 36989447
[No Abstract] [Full Text] [Related]
7. Impact of cardiovascular disease on health care economic burden and resource utilization: a retrospective cohort study in adults in the United States with type 2 diabetes with or without stroke, myocardial infarction, and peripheral arterial disease.
King A; Rajpura J; Liang Y; Paprocki Y; Uzoigwe C
Curr Med Res Opin; 2022 Nov; 38(11):1831-1840. PubMed ID: 36134459
[TBL] [Abstract][Full Text] [Related]
8. Real-world treatment modalities, health care resource utilization, and costs among commercially insured patients with newly diagnosed major depressive disorder in the United States.
Pizzicato LN; Xie RZ; Yang Y; Grabner M; Chapman RH
J Manag Care Spec Pharm; 2023 Jun; 29(6):614-625. PubMed ID: 37276037
[No Abstract] [Full Text] [Related]
9. Effect of Weight Change on Economic Outcomes Among Persons with Type 2 Diabetes Mellitus in the United States: Beyond Glycemic Control.
Karkare S; Fridman M; Dang-Tan T; Lu J; Smolarz BG; DeKoven M; Iyer NN
J Manag Care Spec Pharm; 2019 Jun; 25(6):658-668. PubMed ID: 30730232
[TBL] [Abstract][Full Text] [Related]
10. Incremental cost burden among patients with severe uncontrolled asthma in the United States.
Burnette A; Wang Y; Rane PB; Chung Y; Princic N; Park J; Llanos JP; Lindsley AW; Ambrose CS
J Manag Care Spec Pharm; 2023 Jul; 29(7):825-834. PubMed ID: 37404066
[No Abstract] [Full Text] [Related]
11. Health care resource utilization and costs among individuals with vs without Huntington disease in a US population.
To TM; Exuzides A; Abbass IM; Patel AM; Ta JT; Surinach A; Fuller RLM; Luo J
J Manag Care Spec Pharm; 2022 Nov; 28(11):1228-1239. PubMed ID: 36282937
[No Abstract] [Full Text] [Related]
12. Medical Costs Associated with Severity of Chronic Kidney Disease in Type 2 Diabetes Mellitus in Singapore.
Lim GJ; Liu YL; Low S; Ang K; Tavintharan S; Sum CF; Lim SC
Ann Acad Med Singap; 2020 Oct; 49(10):731-741. PubMed ID: 33283836
[TBL] [Abstract][Full Text] [Related]
13. The Economic Burden of End-Organ Damage Among Medicaid Patients with Sickle Cell Disease in the United States: A Population-Based Longitudinal Claims Study.
Campbell A; Cong Z; Agodoa I; Song X; Martinez DJ; Black D; Lew CR; Varker H; Chan C; Lanzkron S
J Manag Care Spec Pharm; 2020 Sep; 26(9):1121-1129. PubMed ID: 32597290
[TBL] [Abstract][Full Text] [Related]
14. Chronic kidney disease in US adults with type 2 diabetes: an updated national estimate of prevalence based on Kidney Disease: Improving Global Outcomes (KDIGO) staging.
Bailey RA; Wang Y; Zhu V; Rupnow MF
BMC Res Notes; 2014 Jul; 7():415. PubMed ID: 24990184
[TBL] [Abstract][Full Text] [Related]
15. The economic burden of progressive chronic kidney disease among patients with type 2 diabetes.
Vupputuri S; Kimes TM; Calloway MO; Christian JB; Bruhn D; Martin AA; Nichols GA
J Diabetes Complications; 2014; 28(1):10-6. PubMed ID: 24211091
[TBL] [Abstract][Full Text] [Related]
16. Economic burden of invasive
Hernandez-Pastor L; Geurtsen J; Baugh B; El Khoury AC; Kalu N; Krishnarajah G; Gauthier-Loiselle M; Bungay R; Cloutier M; Saade E
J Manag Care Spec Pharm; 2023 Aug; 29(8):873-883. PubMed ID: 37523312
[No Abstract] [Full Text] [Related]
17. Clinical and Economic Burden of Commercially Insured Patients with Acromegaly in the United States: A Retrospective Analysis.
Placzek H; Xu Y; Mu Y; Begelman SM; Fisher M
J Manag Care Spec Pharm; 2015 Dec; 21(12):1106-12. PubMed ID: 26679960
[TBL] [Abstract][Full Text] [Related]
18. Prolonged oral corticosteroid treatment in patients with systemic lupus erythematosus: An evaluation of 12-month economic and clinical burden.
Huang SP; DerSarkissian M; Gu YM; Duh MS; Wang MJ; Benson J; Vu J; Averell C; Bell CF
J Manag Care Spec Pharm; 2023 Apr; 29(4):365-377. PubMed ID: 36989451
[No Abstract] [Full Text] [Related]
19. Differences in All-Cause Health Care Utilization and Costs in a Type 2 Diabetes Mellitus Population with and Without a History of Cardiovascular Disease.
Mehta S; Ghosh S; Sander S; Kuti E; Mountford WK
J Manag Care Spec Pharm; 2018 Mar; 24(3):280-290. PubMed ID: 29485954
[TBL] [Abstract][Full Text] [Related]
20. Economic burden of comorbid chronic kidney disease and diabetes.
McQueen RB; Farahbakhshian S; Bell KF; Nair KV; Saseen JJ
J Med Econ; 2017 Jun; 20(6):585-591. PubMed ID: 28128669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]